<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01814540</url>
  </required_header>
  <id_info>
    <org_study_id>264294</org_study_id>
    <nct_id>NCT01814540</nct_id>
  </id_info>
  <brief_title>Bovine Milk Oligosaccharide Study</brief_title>
  <acronym>BMO</acronym>
  <official_title>Pilot Study: Tolerability of Feeding Different Doses of Bovine Milk Oligosaccharides for Modifying Gastrointestinal Function in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairy Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate tolerability and effectiveness in consumption of
      the complex indigestible sugars from dairy products called bovine milk oligosaccharides (BMO)
      to enrich intestinal microflora toward beneficial populations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-blind crossover study designed to determine if BMO at two different doses
      selectively enrich beneficial bacteria in the human gut and will be tolerated in healthy
      participants compared with a placebo control supplement. Each participant will consume two
      sachets of supplement for eleven days, separated by a two-week washout before starting the
      second and third arms. To determine the effect of dose, the placebo-control supplement will
      be administered in the first arm, followed by the low and high dose. Participants will
      collect stool and first morning urine and study personnel collected blood from each
      participant at baseline (day 0) and at the end (Day 11) of each study arm for all three arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>Change from baseline to day 11</time_frame>
    <description>Gut microbiota will be analyzed for 16s rRNA by next generation sequencing, terminal restriction fragment length polymorphism, and quantitative polymerase chain reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Metabolites</measure>
    <time_frame>Days 0, 4, 11</time_frame>
    <description>First morning urine samples will be analyzed by nuclear magnetic resonance spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lipid Profile</measure>
    <time_frame>Day 0 and Day 11</time_frame>
    <description>Fasting plasma lipid profile (total triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol) will be analyzed by enzymatic analysis by UC Davis Pathology Lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose</measure>
    <time_frame>Day 0 and Day 11</time_frame>
    <description>Fasting plasma glucose will be measured by enzyme analysis by UC Davis Pathology Lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Macronutrient Intake</measure>
    <time_frame>Day 0</time_frame>
    <description>Participants will fill out three-day diet records for two weekdays and one weekend before starting each dietary supplemental arm in order to determine if intake of BMO vs. placebo control influences habitual dietary intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut Tolerability</measure>
    <time_frame>Days Minus 7 and Days 0-10</time_frame>
    <description>Participants will fill out a standardized gut tolerability questionnaire (Pedersen et al., 1997) rating their symptoms of gut and stomach discomfort on a 0-10 discretized visual analog scale daily seven days before starting each arm and on five different occasions on Days 0-10 during each study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>Minus Day 7 and Days 0-10</time_frame>
    <description>Participants will fill out the Bristol Stool Scale when they have bowel movements seven days before starting each study arm and daily during each study arm. The discretized visual analog scale 1-7 describes hardness to softness of stool.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo Control, Glucose polymer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment 1: Polycose Glucose Polymer Module powder (Abbott Nutrition, Abbott Park, Illinois 60064), fed as 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2: Low-Dose BMO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 2: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 25% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period
Fiber intake was 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 3: High-Dose BMO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 3: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 35% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period
Fiber intake was 35% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bovine Milk Oligosaccharide</intervention_name>
    <description>The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.</description>
    <arm_group_label>Treatment 2: Low-Dose BMO</arm_group_label>
    <arm_group_label>Treatment 3: High-Dose BMO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Glucose Polymer</intervention_name>
    <arm_group_label>Placebo Control, Glucose polymer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women aged 18-40 years old

          -  BMI 18-25

          -  Born by vaginal birth (not C-section)

          -  Breastfed for a minimum of 2 months after birth

        Exclusion Criteria:

          -  Individuals who regularly consume high fiber cereals or fiber supplements

          -  Individuals who frequently consume yogurt (eligible if willing to refrain consumption
             during the study period)

          -  Individuals who are lactose intolerant and/or allergic to dairy or wheat

          -  Individuals who use tobacco products

          -  Individuals who are pregnant or lactating

          -  Individuals with a known presence of gastrointestinal/malabsorption disorders or
             autoimmune disease

          -  Individuals taking prescription or over-the-counter medications that include
             pre/probiotics, corticosteroids, anti-obesity agents, laxatives, and lipid- altering
             medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Barile, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Smilowitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Bruce German, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolyn Slupsky, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela M Zivkovic, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Mills, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ffhi.ucdavis.edu/human-studies/bovine-milk-oligosaccharides</url>
    <description>Details for this research project is available through the UC Davis Foods for Health Institute website</description>
  </link>
  <reference>
    <citation>Pedersen A, Sandstr√∂m B, Van Amelsvoort JM. The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females. Br J Nutr. 1997 Aug;78(2):215-22.</citation>
    <PMID>9301412</PMID>
  </reference>
  <reference>
    <citation>Tao N, DePeters EJ, Freeman S, German JB, Grimm R, Lebrilla CB. Bovine milk glycome. J Dairy Sci. 2008 Oct;91(10):3768-78. doi: 10.3168/jds.2008-1305.</citation>
    <PMID>18832198</PMID>
  </reference>
  <reference>
    <citation>Tao N, DePeters EJ, German JB, Grimm R, Lebrilla CB. Variations in bovine milk oligosaccharides during early and middle lactation stages analyzed by high-performance liquid chromatography-chip/mass spectrometry. J Dairy Sci. 2009 Jul;92(7):2991-3001. doi: 10.3168/jds.2008-1642.</citation>
    <PMID>19528576</PMID>
  </reference>
  <reference>
    <citation>Barile D, Tao N, Lebrilla CB, Coisson JD, Arlorio M, German JB. Permeate from cheese whey ultrafiltration is a source of milk oligosaccharides. Int Dairy J. 2009 Sep 1;19(9):524-530.</citation>
    <PMID>20161544</PMID>
  </reference>
  <reference>
    <citation>Barile D, Marotta M, Chu C, Mehra R, Grimm R, Lebrilla CB, German JB. Neutral and acidic oligosaccharides in Holstein-Friesian colostrum during the first 3 days of lactation measured by high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. J Dairy Sci. 2010 Sep;93(9):3940-9. doi: 10.3168/jds.2010-3156.</citation>
    <PMID>20723667</PMID>
  </reference>
  <reference>
    <citation>Strum JS, Aldredge D, Barile D, Lebrilla CB. Coupling flash liquid chromatography with mass spectrometry for enrichment and isolation of milk oligosaccharides for functional studies. Anal Biochem. 2012 May 15;424(2):87-96. doi: 10.1016/j.ab.2012.02.012. Epub 2012 Feb 25.</citation>
    <PMID>22370281</PMID>
  </reference>
  <reference>
    <citation>Sundekilde UK, Barile D, Meyrand M, Poulsen NA, Larsen LB, Lebrilla CB, German JB, Bertram HC. Natural variability in bovine milk oligosaccharides from Danish Jersey and Holstein-Friesian breeds. J Agric Food Chem. 2012 Jun 20;60(24):6188-96. doi: 10.1021/jf300015j. Epub 2012 Jun 6.</citation>
    <PMID>22632419</PMID>
  </reference>
  <reference>
    <citation>Zivkovic AM, Barile D. Bovine milk as a source of functional oligosaccharides for improving human health. Adv Nutr. 2011 May;2(3):284-9. doi: 10.3945/an.111.000455. Epub 2011 Apr 30. Review.</citation>
    <PMID>22332060</PMID>
  </reference>
  <reference>
    <citation>Garrido D, Barile D, Mills DA. A molecular basis for bifidobacterial enrichment in the infant gastrointestinal tract. Adv Nutr. 2012 May 1;3(3):415S-21S. doi: 10.3945/an.111.001586. Review.</citation>
    <PMID>22585920</PMID>
  </reference>
  <reference>
    <citation>Aldredge DL, Geronimo MR, Hua S, Nwosu CC, Lebrilla CB, Barile D. Annotation and structural elucidation of bovine milk oligosaccharides and determination of novel fucosylated structures. Glycobiology. 2013 Jun;23(6):664-76. doi: 10.1093/glycob/cwt007. Epub 2013 Feb 22.</citation>
    <PMID>23436288</PMID>
  </reference>
  <reference>
    <citation>Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997 Sep;32(9):920-4.</citation>
    <PMID>9299672</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2013</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

